Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: CD26 antigen antagonists - Biovitrum

Next Previous
X
Search
Drug Profile

Research programme: CD26 antigen antagonists - Biovitrum

Alternative Names: Dipeptidyl peptidase IV anatagonists - Biovitrum; DPP-IV antagonists - Biovitrum; SNT 189546

Latest Information Update: 24 Feb 2010

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Santhera Pharmaceuticals
  • Developer Swedish Orphan Biovitrum
  • Class Antihyperglycaemics
  • Mechanism of Action Dipeptidyl peptidase 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 14 Jan 2010 Biovitrum has merged with Swedish Orphan to form Swedish Orphan Biovitrum
  • 12 Mar 2008 This programme is still in preclinical development
  • 17 Aug 2005 Santhera Pharmaceuticals and Biovitrum AB have entered into an agreement that gives Biovitrum exclusive worldwide rights to develop and commercialise compounds from Santhera's DDP IV inhibitor programme for a range of metabolic diseases

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top